Recognition and treatment of hyponatremia in acutely ill hospitalized patients

Clinical Therapeutics

Volumn 29, Issue 2, 2007, Pages 211-229

  Patel, Gourang P ^a   Balk, Robert A ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

aquaretics; AVP receptor antagonists; euvolemia; hyponatremia; SIADH

Indexed keywords

CONIVAPTAN; LIXIVAPTAN; TOLVAPTAN;

ARTICLE; CONGESTIVE HEART FAILURE; CRITICALLY ILL PATIENT; ELECTROLYTE DISTURBANCE; HOSPITALIZATION; HUMAN; HYPERVOLEMIA; HYPONATREMIA; INTENSIVE CARE UNIT; MEDICAL LITERATURE; MORBIDITY; MORTALITY; PHYSICIAN; SODIUM METABOLISM; VASOPRESSIN RELEASE; WATER METABOLISM;

ARGININE VASOPRESSIN; AZEPINES; BENZAMIDES; BENZAZEPINES; CRITICAL ILLNESS; HUMANS; HYPONATREMIA; INPATIENTS; PRACTICE GUIDELINES; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, VASOPRESSIN;

EID: 34247518318     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2007.02.004     Document Type: Article

References (94)

1. DeVita M.V., Gardenswartz M.H., Konecky A., and Zabetakis P.M. Incidence and etiology of hyponatremia in an intensive cure unit. Clin Nephrol 34 (1990) 163-166
2. Baran D., and Hutchinson T.A. The outcome of hyponatremia in a general hospital population. Clin Nephrol 22 (1984) 72-76
3. Anderson R.J., Chung H.M., Kluge R., and Schrier R.W. Hyponatremia: A prospective analysis of its epidemiology and the pathogenetic role of vasopressin. Ann Intern Med 102 (1985) 164-168
4. Oh M.S. Pathogenesis and diagnosis of hyponatremia. Nehpron 92 Suppl 1 (2002) 2-8
5. Flear C.T., Gill G.V., and Burn J. Hyponatraemia: Mechanisms and management. Lancet 2 (1981) 26-31
6. Verbais J.G. Disorders of body water homeostasis. Best Pract Res Clin Endocrinol Metab 17 (2003) 471-503
7. Wong L.L., and Verbalis J.G. Systemic diseases associated with disorders of water homeostasis. Endocrinol Metab Clin North Am 31 (2002) 121-140
8. Chan M.C., Chang H.W., Cheng C.L., et al. Risk stratification of in-hospital mortality in patients hospitalized for chronic congestive heart failure secondary to non-ischemic cardiomyopathy. Cardiology 100 (2003) 136-142
9. Oren R.M. Hyponatremia in congestive heart failure. Am J Cardiol 95 (2005) 2B-7B
10. Lee D.S., Austin P.C., Rouleau J.L., et al. Predicting mortality among patients hospitalized for heart failure: Derivation and validation of a clinical model. JAMA 290 (2003) 2581-2587
11. Nussey S.S., and Whitehead S.A. Aldosterone and the control of salt and water balance. Endocrinology: An Integrated Approach (2001), BIOS Scientific Publishers, Ltd, Oxford, United Kingdom 150-156
12. Marieb E.N. Essentials of Human Anatomy & Physiology. 6th ed. (2004), Pearson Benjamin Cummings, San Francisco, Calif.
13. Li N., and Wang J.A. Brain natriuretic peptide and optimal management of heart failure. J Zhejiang Univ Sci B 6 (2005) 877-884
14. Mukoyama M., Nakao K., Hossoda K., et al. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuredic peptide system, atrial natriureticpeptide and brain natriuretic peptide. J Clin Inves 87 (1991) 1402-1412
15. Yoshimura M., Yasue H., Okumura K., et al. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation 87 (1993) 464-469
16. Richards A.M., Crozier I.G., Holmes S.J., et al. Brain natriuretic peptide: Natriuretic and endocrine effects in essential hypertension. J Hypertens 11 (1993) 163-170
17. Jensen K.T., Cartens J., and Pedersen E.B. Effect of BNP on renal hemodynamics, tubular function and vasoactive hormones in humans. Am J Physiol 274 (1998) F63-F72
18. Adrogue H.J., and Madias N.E. Hyponatremia. N Engl J Med 342 (2000) 1581-1589
19. Holmes C.L., Landry D.W., and Granton J.T. Science review: Vasopressin and the cardiovascular system part 1-recepror physiology. Crit Care 7 (2003) 427-434
20. Nakamura Y., Haneda T., Osaki J., et al. Hypertrophic growth of cultured neonatal rat heart cells mediated by vasopressin V(1A) receptor. Eur J Pharmacol 391 (2000) 39-48
21. Goldsmith S.R., and Gheorghiade M. Vasopressin antagonism in heart failure. J Am Coll Cardiol 46 (2005) 1783-1791
22. Thibonnier M., Conarty D.M., Preston J.A., et al. Molecular pharmacology of human vasopressin receptors. Adv Exp Med Biol 449 (1998) 251-276
23. Ferguson J.W., Therapondos G., Newby D.E., and Hayes P.C. Therapeutic role of vasopressin receptor antagonism in patients with liver cirrhosis. Clin Sci (Lond) 105 (2003) 1-8
24. Knepper M.A. Molecular physiology of urinary concentrating mechanism: Regulation of aquaporin water channels by vasopressin. Am J Physiol 272 (1997) F3-F12
25. Boyer T.D. Aquaretics in cirrhotics with hyponatremia. J Gastroenterol Hepatol 19 (2004) S191-S193
26. Gerbes A.L., Gulberg V., Gines P., et al., VPA Study Group. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: A randomized double-blind multicenter trial. Gastroenterology 124 (2003) 933-939
27. 2 antagonist conivaptan in euvolemic or hypervolemic hyponatremia. Program and abstracts of the American Society of Nephrology Renal Week 2004 (October 27-November 1, 2004)
28. 2-receptor blockade with tolvaptan in patients with chronic heart failure: Results from a double-blind, randomized trial. Circulation 107 (2003) 2690-2696
29. Gheorghiade M., Gattis W.A., O'Connor C.M., et al., Acute and Chronic Therapeutic Impact of a vasopressin Antagonist in Congestive Heart Failure (ACT-IV in CHF) Investigators. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: A randomized controlled trial. JAMA 291 (2004) 1963-1971
30. Abstract 839-1. Gheorghiade M., Konstam M.A., Udelson J.E., et al. Vasopressin in receptor blockade with tolvaptan in chronic heart failure: Differential effects in normonatremic and hyponoremic patients. J Am Coll Cardiol 39 Suppl 1 (20002) 171
31. (Suppl). Gheorghiade M., Zimmer C., Czerwiec F., et al. Improvement in hyponatremia: Insights from the acute and chronic therapeutic impact of a vasopressin antagonist in chronic hear failure. Abstract 352. Eur J Heart Fail 4 (2005) 79
32. Gheorghiade M., Gattis W.A., Barbagelata A., et al., Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure Investigators. Rationale and study design for a multicenter, randomized, double-blind, placebocontrolled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure. Am Heart J 145 Suppl 2 (2003) S51-S54
33. 2 antagonist, increases serum sodium and effec tive water clearance in hyponatremia. Program and abstracts of the American Society of Nephrology Renal Week 2004 (October 27-November 1, 2004)
34. 2 antagonist in cirrhotic patients with ascites. Hepatology 36 (2002) 1197-1205
35. Udelson J.E., Smith W.B., Hendrix G.H., et al. Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 104 (2001) 2417-2423
36. 2 antagonist (conivaptan) increased serum sodium concentration in patients with hyponatremia secondary to congestive heart failure. J Card Fail 11 Suppl 6 (2005) S120
37. 2 antagonist, increased serum sodium 2 days and 4 or 5 days after administration in patients with hyponatremia. Program and abstracts of the Endocrine society's 87th Annual Meeting (June 4-7, 2005)
38. 2 antagonist conivaptan increased serum sodium concentration and effective water clearance in euvolemic and hypervolemic hyponatremia: Summary of three phase 3 clinical trials. Program and abstracts of the Endocrine Society's 87th Annual Meeting (June 4-7, 2005)
39. 2 antagonist (conivaptan) increases serum sodium concentration and effective water clearance inpatients withhyponatremia. Abstract 036. J Card Fail 10 (2004) S2-s27
40. Wong F., Blei A.T., Blendis L.M., and Thuluvath P.J. A vasopressn receptor antagonist (VPA-985) improves se rum sodium concentration in patients with hyponatremia: A multicenter, randomized,placebo-controlled trial. Hepatology 37 (2003) 182-191
41. Goh K.P. Management of hyponatremia. Am Fam Physician 69 (2004) 2387-2394
42. Masoudi F.A., Baillie C.A., Wang Y., et al. The complexity and cost of drug regimens patients hospitalized with heart failure in the United States, 1998-2001. Arch Intern Med 165 (2005) 2069-2076
43. 2 receptor antagonists. Cardiovasc Res 51 (2001) 391-402
44. Goldsmith S.R., Francis G.S., and Cowley Jr. A.W. Arginine vasopressn and the renal response to water loading in congestive hear failure. Am J Cardiol 58 (1986) 295-299
45. Better O.S., and Schrier R.W. Disturbed volume homeostasis in patients with cirrhosis of the liver. Kidney Int (1983) 303-311
46. Bichet D., Szatalowicz V., Chaimovitz C., and Schrier R.W. Role of vasopressin in abnormal water excretion in cirrhotic patients. Ann Intern Med 96 (1982) 413-417
47. [published correction appears in N Engl J Med. 1989;320: 676]. Schrier R.W. Pathogenesis of sodium and water reention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy. N Engl J Med 319 (1988) 1065-1072
48. Angeli R., Wong F., Watson H., Gines P., and CAPPS Investigators. Hyponatremia in cirrhosis: Results of a patient population survey. Hepatology 44 (2006) 1535-1542
49. Chung H.M., Kluge R., Schrier R.W., and Anderson R.J. Postoperative hyponatremia. A prospective study. Arch Intern Med. 146 (1986) 333-336
50. Baylis P.H. The syndrome of inappropriate antidiuretic hormone secretion. Int J Biochem Cell Biol 35 (2003) 1495-1499
51. Siragy H.M. Hyponatremia, fluidelectrolyte disorders, and the syndrome of inappropriate antidiuretic hormone secretion: Diagnosis and treatment options. Endocr Pract 12 (2006) 446-457
52. Bartter F.C., and Schwartz W.B. The syndrome of inappropriate secretion of antidiuretic hormine. Am J Med 42 (1967) 790-806
53. Robertson G.L. Regulation of alnine vasopressin in the syndrome of inappropriate antidiuresis. Am J Med 119 Suppl 1 (2006) S36-S42
54. Arieff A.I., Llach F., and Massry S.G. Neurological manifestations and morbidity of hyponatremia: Correlation with brain water and electrolytes. Medicine (Baltimore) 55 (1976) 121-129
55. Sterns R.H., Cappuccio J.D., Silver S.M., and Cohen E.P. Neurologic sequelae after treatment of severe hyponatremia: A multicenter perspective. J Am Soc Nephrol 4 (1994) 1522-1530
56. Verbalis J.G. Hyponanemia: Epidemiology, pathophysiology, and therapy. Curr Opin Nephrol Hyperteins 2 (1993) 636-652
57. Koay E.S., and Walmsley N. Sodium and wate, metabolism. A Prime of Chemical Pathology (1996), World Scientific Publishing Co, Singapore 1-24
58. Decaux G., Musch W., and Soupart A. Hyponatremia in the intensive care: From diagnosis to treatment. Acta Clin Belg. 55 (2000) 68-78
59. Adrogue H.J. Consequences of inadequate management of hyponatremia. Am J Nephrol 25 (2005) 240-249
60. 2 receptor antagonists. J Mol Endocrinol 29 (2002) 1-9
61. Gross P., Reimann D., Henschkowski J., and Damian M. Treatment of severe hyponatremia: Conventional and novel aspects. J Am Soc Nephrol 12 Suppl 17 (2001) S10-S14
62. Fraser C.L., and Arieff A.I. Epidemiology, pathophysiology, and management of hyponatremic encephalopathy. Am J Med 102 (1997) 67-77
63. Pasantes-Morales H., Lezama R.A., Ramos-Mandujano G., and Tuz K.L. Mechanisms of cell volume regulation of hypo-osmolality. Am J Med 119 Suppl 1 (2006) S4-S11
64. Ayus J.C., and Arieff A.I. Pulmonary complications of hyponatr mic encephalopathy. Noncardiogenic pul monary edema and hypercapnic respiratory failure. Chest 107 (1995) 517-521
65. Kraft M.D., Btaiche I.M., Sack G.S., and Kudsk K.A. Treatment of electrolyte disorders inadult patients in the in-tensive cor unit. Am J Health Syst Pharm 62 (2005) 1663-1682
66. Adrogue H.J., and Madias N.E. Aiding fluid prescription for the dysnatremias. Intensive Care Mod 23 (1997) 309-316
67. Ayus J.C., and Arieff A.I. Chronic hyponatremic encephalopathy in postmenopausal women: Association of therapies with morbidity and morbidity. JAMA 281 (1999) 2299-2304
68. Norenberg M.D., Leslie K.O., and Robertson A.S. Association between rise in serum sodium and central pontine myeinolysis. Ann Neurol 11 (1982) 128-135
69. Sterns R.H., Riggs J.E., and Schochet Jr. S.S. Osmotic demyelination syndrome following correction of hyponatremi (1986) 1535-1542
70. Sterns R.H. Severe symptomatic hyponatremia: Treatment and outcome. A study of 64 cases. Ann Intern Med 107 (1987) 656-664
71. Vachharajani T.J., Zaman F., and Abreo K.D. Hyponatremia in critically ill patients. J Intensive Care Med 18 (2003) 3-8
72. Vaprisol (conivaptan hydrochloride injection) [package insert] (2006), Astellas Pharma US, Inc., Deerfield, Ull
73. Sonnenblick M., Friedlander Y., and Rosin A.J. Diuretic-induced sae, hyponatremia. Review and analysis of 129 reported patients. Chest 103 (1993) 601-606
74. Spiral A. Diuretic-induced hyponatremia. Am J Nephrol. 19 (1999) 447-452
75. Kraue K.H., Rascher W., and Berlit P. Plasma arginine vasopressin concentrations in epileptics under monotherapy. J Neurol 230 (1983) 193-196
76. Craig S. Phenytoin poisoning. Neurocrit Care 3 (2005) 61-170
77. Verbalis J.G. AVP receptor antagonist as aquaretics: Review and assessment of clinical data. Cleve Clin J Med 73 Suppl 3 (2007) S24-S33
78. Orlandi C., Zimmer C.A., and Gheorghiade M. Role of vasopressin antagonists inthemanagement ofacute decompensated heart failure. Curr Heart Fail Rep 2 (2005) 131-139
79. 2 vasopressin antagonists in hyponatrrmia. Cardiovasc Res 51 (2001) 403-408
80. Thibonnier M. Vasopressin receptor antagonists in heart failure. Curr Opin Int. 3 (2003) 683-687
81. Greenherg A., and Verbais J.G. Vasopressin ruceptor antagonists. Kidney Int 69 (2006) 2124-2130
82. 2 receptor antagonist, in dogs. Eur J Pharmacol 321 (1997) 225-23O0
83. 2 receptor antagonist, in dogs with pacinginduced congestive heart failure. Eur J Pharmacol. 376 (1999) 239-246
84. 2-receptor antagonist: Pharmacological profile and aquaretic effect by single and multiple oraldosing in rats. J Pharmcol Exp Ther 287 (1998) 860-867
85. Hirano T., Yamamura Y., Nakamura S., et al. Effects of the V(2)-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and incombination in rats. J Pharmacol Exp Ther 292 (2000) 288-294
86. Naitoh W., Suzuki H., Murakami W., et al. Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs. Am J Physiol 267 (1994) H2245-H2254
87. 2 receptor antagonist on the development of heart failure in rats. J Cardiovasc Pharmacol 27 (1996) 275-282
88. 2 receptor antagonist, in patients with NYHA classIII/IV heart failure. Circulation 102 (2000) 11-535
89. 2 receptor antagonist. Eur Heart J 21 (2000) 345
90. 2 antagonist conivaptan increases serum sodium concentration and effective water clearance in hyponatremia. J Am Soc Nephrol 15 (2004) 356A
91. Cleland J.G., Freemantle N., Kay G., et al. Clinical trials update from the American Heart Association meeting: Omegas fatty acids and arrhythmia risk in patients with an implantable defibrillator; ACTIV in CHF, VALIANT, the Hanover autologous bone marrow transplantation study, SPORTIF V, ORBIT and PAD and DEFINITE. Eur J Heart Fail 6 (2004) 109-115
92. Gheorghiade M., Orlandi C., Burnett J.C., et al. Rationale and design of the multicemyr, randomized, double-blind, placebo-controlled study to evaluate the efficacy of vasopressin antagonism in heart failure: Outcome study with tolvaptan (EVEREST). J Card Fail 11 (2005) 260-269
93. 2-receptor antagonist, for hyponmcremia. N Engl J Med 355 (2006) 2099-2112
94. Gheorghiade M., Gottlieb S.S., Udelson J.E., et al., Tolvaptan Investigators. Vasopressin V92) receptor blockade with tolvaptan tolvaptan versus fluid restriction in the treatment of hyponatremia. Am J Cardio 97 (2006) 1064-1067